ST Pharm FY 2025 Annual ReportBeta
ST Pharm annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 18, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
ST Pharm FY 2025 Annual Report Analysis
Business Overview
- • Oligonucleotide CDMO global rank 3rd with new 2nd oligo plant started Q4 2025, contributing to sales from 2026
- • Entered mRNA business Nov 2020; secured 177B KRW LNP lipid supply contract May 2022 and SmartCap® supply contract Aug 2024
Management Discussion & Analysis
- • Revenue KRW 331.7B (+21.2% YoY), Operating profit KRW 54.9B (+98.4%), Net income KRW 54.6B (+68.1%) in FY2025
- • Oligo API CDMO segment drove growth with revenue up 35% to KRW 237.6B; management cites "commercialization project increase to 5 cases"
Risk Factors
- • USD foreign currency exposure KRW 133.38B assets, KRW 13.14B liabilities, 10% USD move ±KRW 9.16B after-tax profit impact FY2025
- • Short-term financial liabilities within 1 year KRW 64.84B (buying payables KRW 11.80B, lease liabilities KRW 1.28B, borrowings KRW 31.65B, other liabilities KRW 20.39B) FY2025
ST Pharm FY 2025 Key Financial MetricsDART
Total Assets
KRW 782.6B
▲ +8.4% YoY
Operating Cash Flow
KRW 14.0B
▼ -87.2% YoY
CapEx
KRW 47.1B
▼ -43.2% YoY
Source: KIFRS consolidated financial data from ST Pharm annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding